Skip to main content
Premium Trial:

Request an Annual Quote

Cepheid Gets FDA OK for Thrombosis Test

NEW YORK (GenomeWeb News) – Cepheid said after the close of the market Thursday that the US Food and Drug Administration has cleared for marketing its Xpert HemosIL FII & FV test.

The test detects Factor II and V Leiden genetic variations associated with thrombophilia. It runs on the firm's GeneXpert system and provides results in just over 30 minutes. The test will be distributed exclusively by Instrumentation Laboratory.

The Xpert HemosIL FII & FV is Cepheid's eighth test to receive FDA clearance. IL launched the test in Europe in March 2008, and its CEO, Josep Manent, said in a statement that customer response there has been "extremely positive."

The Scan

Wolf Howl Responses Offer Look at Vocal Behavior-Related Selection in Dogs

In dozens of domestic dogs listening to wolf vocalizations, researchers in Communication Biology see responses varying with age, sex, reproductive status, and a breed's evolutionary distance from wolves.

Facial Imaging-Based Genetic Diagnoses Appears to Get Boost With Three-Dimensional Approach

With data for more than 1,900 individuals affected by a range of genetic conditions, researchers compared facial phenotype-based diagnoses informed by 2D or 3D images in the European Journal of Human Genetics.

Survey Suggests Multigene Cancer Panel VUS Reporting May Vary Across Genetic Counselors

Investigators surveyed dozens of genetic counselors working in clinical or laboratory settings, uncovering attitudes around VUS reporting after multigene cancer panel testing in the Journal of Genetic Counseling.

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.